W308051 / GSK, WuXi AppTec - LARVOL DELTA

The affinity-optimized bispecific T cell engager W308051 selectively kills PSMA-expressing tumor cells with limited cytokine secretion (AACR 2026) - "W308051 demonstrates a higher binding affinity to PSMA compared to the competitor molecules AMG160 and AMG340 with a KD of 16 pM as shown by surface plasmon resonance and also stronger binding in ELISA and cell-based binding assays. Pharmacokinetic analyses indicate that the use of T cell receptor domains for bispecific antibody assembly confers properties akin to those observed with conventional monoclonal antibodies. Collectively, these findings support the further clinical investigation of W308051 as a promising therapeutic modality for mCRPC."

Bispecific • IO biomarker • Tumor cell • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1